Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExpressGraft-C9T1 in Diabetic Foot Ulcers
NCT02657876Phase 1Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ExpressGraft-C9T1 in diabetic foot ulcer (DFU), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Number of participants with adverse events. Started Jan 2018; status: completed.
02
Drugs
ExpressGraft-C9T1
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02657876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657876.